Amit Banga, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Banga’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C177767 · Current
Licensed to practise in California · since 2022 · expires 2028-06-30 · Jiwaji University, Gajra Raja Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas Q0406Physician License · since 2014 · expires 2028-08-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$185,907
Medicare paid this office $185,907 for 164 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $71,410 | $105 |
| Critical care, first 30-74 minutes | 25 | $35,386 | $185 |
| Long return visit (40+ min) | 94 | $17,236 | $122 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 61 | $15,848 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $11,482 | $153 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $71,410 | $105 |
| Critical care, first 30-74 minutes | 25 | $35,386 | $185 |
| Long return visit (40+ min) | 94 | $17,236 | $122 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 61 | $15,848 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $11,482 | $153 |
| Aspiration of subsequent secretions of lung airway using an endoscope during same hospital stay | 26 | $9,764 | $116 |
| Aspiration of initial secretion of lung airway using an endoscope | 85 | $9,600 | $59 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 90 | $4,571 | $19 |
| Hospital discharge day management, more than 30 minutes | 37 | $4,171 | $104 |
| Long return visit (40+ min) | 13 | $1,823 | $114 |
| Biopsy of lobe of lung using an endoscope, each additional lobe | 11 | $632 | $42 |
Who their Medicare patients are
164 Original Medicare patients in 2024. Average age 63 · Under 65 43% · 85 and older 0% · Women 42% · Also on Medicaid 41% · Health risk score 4.28. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 70% · COPD 54% · Coronary heart disease 43% · Heart failure 40% · Atrial fibrillation 39% · Depression 31% · Stroke 12% · Dementia 11% · Cancer 10%.
The office billed $1,667,402, Medicare allowed $235,398 and paid $185,907; for 1,804 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 164 | 1,804 | 63 | 4.28 | $1,667,402 | $185,907 |
| 2023 | 155 | 1,295 | 64 | 3.81 | $1,019,906 | $138,810 |
| 2022 | 181 | 1,053 | 66 | 3.50 | $535,163 | $90,182 |
| 2021 | 134 | 986 | 67 | 3.89 | $463,190 | $72,345 |
| 2020 | 167 | 1,024 | 66 | 3.58 | $459,318 | $72,532 |
| 2019 | 215 | 1,289 | 65 | 3.59 | $647,116 | $98,673 |
| 2018 | 210 | 1,406 | 65 | 3.40 | $593,950 | $99,846 |
| 2017 | 235 | 1,487 | 64 | 3.09 | $481,306 | $98,157 |
| 2016 | 202 | 1,194 | 64 | 2.96 | $427,079 | $83,516 |
| 2015 | 216 | 1,078 | 62 | 3.03 | $353,329 | $72,494 |
| 2014 | 96 | 328 | 62 | 2.71 | $149,012 | $27,462 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $58,844 | $107 |
| Long return visit (40+ min) | 99 | $20,042 | $129 |
| Critical care, first 30-74 minutes | 13 | $18,983 | $188 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 40 | $8,795 | $154 |
| Aspiration of subsequent secretions of lung airway using an endoscope during same hospital stay | 22 | $6,613 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,052 | $151 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 65 | $5,910 | $35 |
| Aspiration of initial secretion of lung airway using an endoscope | 51 | $5,149 | $72 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,988 | $105 |
| Long return visit (40+ min) | 11 | $1,436 | $131 |
| Hospital discharge day management, 30 minutes or less | 14 | $1,355 | $71 |
2022: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $46,313 | $85 |
| Critical care, first 30-74 minutes | 17 | $11,498 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,444 | $158 |
| Long return visit (40+ min) | 42 | $5,049 | $110 |
| Aspiration of initial secretion of lung airway using an endoscope | 20 | $3,370 | $112 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 46 | $3,283 | $43 |
| Hospital discharge day management, more than 30 minutes | 29 | $2,428 | $78 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 18 | $2,388 | $133 |
| Long return visit (40+ min) | 14 | $1,883 | $135 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,080 | $60 |
| Test for exercise-induced lung stress | 26 | $468 | $18 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 30 | $441 | $10 |
| Test to measure expiratory airflow and volume | 42 | $291 | $7 |
2021: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $35,651 | $83 |
| Long return visit (40+ min) | 57 | $7,944 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,677 | $160 |
| Aspiration of initial secretion of lung airway using an endoscope | 24 | $4,976 | $100 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 25 | $3,762 | $139 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 52 | $3,588 | $34 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,115 | $88 |
| Hospital discharge day management, 30 minutes or less | 15 | $919 | $57 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 48 | $861 | $10 |
| Test to measure expiratory airflow and volume | 48 | $450 | $7 |
| Test for exercise-induced lung stress | 19 | $329 | $16 |
2020: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $29,847 | $84 |
| Long return visit (40+ min) | 80 | $9,340 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,282 | $162 |
| Critical care, first 30-74 minutes | 12 | $5,036 | $180 |
| Aspiration of initial secretion of lung airway using an endoscope | 25 | $4,993 | $96 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 20 | $3,282 | $143 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 39 | $2,096 | $25 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,471 | $87 |
| Return visit (30+ min) | 23 | $1,235 | $54 |
| Test to measure expiratory airflow and volume | 88 | $920 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 37 | $689 | $10 |
| Test for exercise-induced lung stress | 12 | $265 | $19 |
2019: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $34,322 | $83 |
| Critical care, first 30-74 minutes | 17 | $10,970 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,830 | $161 |
| Long return visit (40+ min) | 72 | $7,877 | $89 |
| Aspiration of initial secretion of lung airway using an endoscope | 27 | $5,890 | $95 |
| Long return visit (40+ min) | 52 | $5,248 | $82 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 30 | $4,328 | $131 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 52 | $3,365 | $30 |
| Initial hospital observation care per day, typically 70 minutes | 13 | $1,923 | $148 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,712 | $86 |
| Return visit (30+ min) | 21 | $1,319 | $63 |
| Return visit (30+ min) | 21 | $1,087 | $49 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,059 | $56 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 49 | $948 | $10 |
| Test to measure expiratory airflow and volume | 69 | $534 | $7 |
| Test to measure expiratory airflow and volume | 16 | $91 | $5 |
2018: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $38,621 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $12,577 | $161 |
| Return visit (30+ min) | 122 | $9,681 | $61 |
| Long return visit (40+ min) | 77 | $8,728 | $84 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 58 | $7,303 | $67 |
| Critical care, first 30-74 minutes | 14 | $5,499 | $177 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 35 | $5,415 | $135 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,167 | $83 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,328 | $58 |
| Test to measure expiratory airflow and volume | 99 | $1,148 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 55 | $953 | $10 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $39,522 | $81 |
| Long return visit (40+ min) | 104 | $13,425 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $11,964 | $160 |
| Return visit (30+ min) | 97 | $7,677 | $58 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 54 | $5,584 | $63 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 29 | $4,553 | $142 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,678 | $84 |
| Pulmonary exercise testing | 66 | $1,695 | $24 |
| Test to measure expiratory airflow and volume | 113 | $1,391 | $7 |
| Hospital discharge day management, 30 minutes or less | 13 | $668 | $48 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 42 | $621 | $10 |
2016: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $28,383 | $81 |
| Long return visit (40+ min) | 107 | $13,486 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,985 | $157 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 34 | $5,709 | $143 |
| Critical care, first 30-74 minutes | 16 | $5,495 | $177 |
| Aspiration of subsequent secretions of lung airway using an endoscope during same hospital stay | 17 | $3,558 | $102 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 47 | $2,880 | $43 |
| Return visit (30+ min) | 37 | $2,614 | $62 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,790 | $85 |
| New patient visit (60+ min) | 13 | $1,742 | $134 |
| Pulmonary exercise testing | 57 | $1,453 | $23 |
| Test to measure expiratory airflow and volume | 105 | $1,444 | $7 |
| Hospital discharge day management, 30 minutes or less | 15 | $921 | $58 |
| Biopsy of lobe of lung using an endoscope, each additional lobe | 12 | $479 | $40 |
2015: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $17,213 | $81 |
| Long return visit (40+ min) | 93 | $11,845 | $80 |
| Critical care, first 30-74 minutes | 24 | $11,104 | $174 |
| Return visit (30+ min) | 91 | $7,113 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,962 | $158 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 17 | $2,508 | $139 |
| Diagnostic exam of lung airway using an endoscope | 12 | $2,446 | $116 |
| New patient visit (60+ min) | 16 | $1,991 | $124 |
| Pulmonary exercise testing | 76 | $1,762 | $23 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 27 | $1,556 | $50 |
| Test to measure expiratory airflow and volume | 122 | $1,426 | $7 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,064 | $53 |
| Biopsy of lobe of lung using an endoscope, each additional lobe | 12 | $472 | $39 |
2014: 5 services
| Long return visit (40+ min) | 62 | $7,142 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,671 | $82 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 15 | $2,378 | $149 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 20 | $740 | $34 |
| Test to measure expiratory airflow and volume | 29 | $210 | $7 |
Medicaid work
$37,358 in 2024
Medicaid paid $37,358 for 541 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 316 | $14,346 |
| Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage | 108 | $11,443 |
| Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with therapeutic aspiration of tracheobronchial tree, initial | 64 | $7,331 |
| Long return visit (40+ min) | 28 | $1,767 |
| BRONCHOSCOPY W/TRANSBRONCHIAL LUNG BX 1 LOBE | 12 | $1,276 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $1,195 |
| 2024 | 541 | 6 | 22 | $37,358 |
| 2023 | 470 | 4 | 19 | $23,957 |
| 2022 | 17 | 1 | 17 | $1,138 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 293 | $11,164 |
| Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage | 91 | $8,498 |
| Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with therapeutic aspiration of tracheobronchial tree, initial | 26 | $2,200 |
| Long return visit (40+ min) | 60 | $2,094 |
2022
| Long return visit (40+ min) | 17 | $1,138 |
Drugs they prescribed that Part D paid
$329,151
Pharmacies billed $329,151 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,185) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
1,086 generic and 99 brand-name prescriptions · $329,151 in drug cost · 144 antibiotic prescriptions to 54 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cresemba | 16 | $96,141 | $6,009 |
| Posaconazole | 82 | $67,884 | $828 |
| Eliquis | 32 | $23,382 | $731 |
| Everolimus | 18 | $20,824 | $1,157 |
| Valganciclovir | 41 | $8,728 | $213 |
See all 30 drugs
| Cresemba | 16 | $96,141 | $6,009 |
| Posaconazole | 82 | $67,884 | $828 |
| Eliquis | 32 | $23,382 | $731 |
| Everolimus | 18 | $20,824 | $1,157 |
| Valganciclovir | 41 | $8,728 | $213 |
| Atovaquone | 15 | $7,659 | $511 |
| Breo Ellipta | 13 | $6,187 | $476 |
| Tacrolimus | 86 | $5,373 | $62 |
| Mycophenolate Mofetil | 37 | $4,518 | $122 |
| Itraconazole | 36 | $4,327 | $120 |
| Clotrimazole | 17 | $983 | $58 |
| Acyclovir | 76 | $885 | $12 |
| Sulfamethoxazole-Trimethoprim | 68 | $740 | $11 |
| Azithromycin | 44 | $427 | $10 |
| Pantoprazole | 46 | $397 | $9 |
| Prednisone | 59 | $396 | $7 |
| Metoprolol | 66 | $252 | $4 |
| Rosuvastatin | 61 | $233 | $4 |
| Gabapentin | 16 | $150 | $9 |
| Pravastatin | 24 | $144 | $6 |
| Carvedilol | 22 | $133 | $6 |
| Furosemide | 27 | $125 | $5 |
| Mirtazapine | 12 | $122 | $10 |
| Amlodipine Besylate | 25 | $120 | $5 |
| Potassium Chloride | 14 | $89 | $6 |
| Levofloxacin | 11 | $37 | $3 |
| Alendronate | 12 | $33 | $3 |
| Famotidine | 11 | $29 | $3 |
| Amoxicillin | 13 | $17 | $1 |
| Hydrochlorothiazide | 16 | $17 | $1 |
Year by year
| 2024 | 1,185 | 150 | 0% (0) | 8% | $329,151 |
| 2023 | 967 | 163 | None | None | $249,349 |
| 2022 | 1,154 | 162 | None | 9% | $221,574 |
| 2021 | 1,562 | 193 | None | 14% | $289,515 |
| 2020 | 1,816 | 214 | 2% (32) | 12% | $357,880 |
| 2019 | 2,164 | 210 | 2% (43) | 15% | $527,707 |
| 2018 | 1,995 | 181 | 4% (70) | 13% | $381,523 |
| 2017 | 1,895 | 178 | 3% (51) | 16% | $490,749 |
| 2016 | 1,378 | 148 | 3% (39) | None | $309,647 |
| 2015 | 1,143 | 128 | 3% (39) | None | $253,724 |
| 2014 | 169 | 48 | None | None | $18,485 |
| 2013 | 71 | 20 | None | 59% | $7,162 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Posaconazole | 23 | $32,197 | $1,400 |
| Itraconazole | 30 | $14,743 | $491 |
| Valganciclovir | 37 | $11,440 | $309 |
| Everolimus | 12 | $7,858 | $655 |
| Mycophenolate Mofetil | 25 | $6,307 | $252 |
| Tacrolimus | 65 | $5,202 | $80 |
| Clotrimazole | 38 | $3,256 | $86 |
| Sucralfate | 11 | $2,817 | $256 |
| Pantoprazole | 50 | $946 | $19 |
| Sodium Polystyrene Sulfonate | 14 | $918 | $66 |
| Sulfamethoxazole-Trimethoprim | 65 | $845 | $13 |
| Acyclovir | 46 | $704 | $15 |
| Gabapentin | 25 | $635 | $25 |
| Azithromycin | 26 | $428 | $16 |
| Amlodipine Besylate | 35 | $389 | $11 |
| Rosuvastatin | 40 | $368 | $9 |
| Prednisone | 46 | $363 | $8 |
| Pravastatin | 23 | $335 | $15 |
| Metoprolol | 28 | $277 | $10 |
| Carvedilol | 11 | $185 | $17 |
| Furosemide | 28 | $134 | $5 |
| Levofloxacin | 12 | $121 | $10 |
| Hydrochlorothiazide | 13 | $27 | $2 |
2022: 25 drugs
| Valganciclovir | 93 | $48,811 | $525 |
| Januvia | 25 | $16,257 | $650 |
| Tacrolimus | 69 | $11,629 | $169 |
| Atovaquone | 13 | $5,445 | $419 |
| Azithromycin | 93 | $2,067 | $22 |
| Dapsone | 18 | $1,424 | $79 |
| Pantoprazole | 68 | $1,317 | $19 |
| Gabapentin | 49 | $898 | $18 |
| Prednisone | 88 | $799 | $9 |
| Nystatin | 12 | $596 | $50 |
| Pravastatin | 33 | $544 | $16 |
| Hydralazine | 16 | $518 | $32 |
| Tamsulosin | 15 | $491 | $33 |
| Sulfamethoxazole-Trimethoprim | 46 | $393 | $9 |
| Levothyroxine | 26 | $384 | $15 |
| Metoprolol | 52 | $344 | $7 |
| Carvedilol | 20 | $311 | $16 |
| Ondansetron | 16 | $305 | $19 |
| Sertraline | 20 | $194 | $10 |
| Amlodipine Besylate | 12 | $175 | $15 |
| Atorvastatin | 13 | $147 | $11 |
| Furosemide | 22 | $142 | $6 |
| Montelukast | 15 | $136 | $9 |
| Warfarin | 11 | $125 | $11 |
| Levofloxacin | 11 | $125 | $11 |
2021: 34 drugs
| Valganciclovir | 126 | $80,181 | $636 |
| Valcyte | 12 | $67,219 | $5,602 |
| Januvia | 17 | $14,832 | $872 |
| Tacrolimus | 73 | $13,845 | $190 |
| Spiriva | 12 | $12,153 | $1,013 |
| Atovaquone | 11 | $10,363 | $942 |
| Humalog Kwikpen U-100 | 12 | $5,194 | $433 |
| Zetia | 12 | $4,377 | $365 |
| Azithromycin | 107 | $3,073 | $29 |
| Pantoprazole | 68 | $1,697 | $25 |
| Mycophenolate Mofetil | 22 | $1,359 | $62 |
| Prednisone | 144 | $1,319 | $9 |
| Pravastatin | 76 | $1,067 | $14 |
| Metoprolol | 54 | $915 | $17 |
| Warfarin | 49 | $731 | $15 |
| Sulfamethoxazole-Trimethoprim | 55 | $594 | $11 |
| Gabapentin | 32 | $484 | $15 |
| Nystatin | 13 | $472 | $36 |
| Diltiazem | 17 | $453 | $27 |
| Furosemide | 55 | $430 | $8 |
| Famotidine | 16 | $379 | $24 |
| Rosuvastatin | 15 | $372 | $25 |
| Tamsulosin | 19 | $360 | $19 |
| Trazodone | 41 | $310 | $8 |
| Levothyroxine | 11 | $227 | $21 |
| Metoclopramide | 11 | $214 | $19 |
| Carvedilol | 17 | $206 | $12 |
| Amlodipine Besylate | 28 | $199 | $7 |
| Sertraline | 23 | $194 | $8 |
| Atorvastatin | 17 | $176 | $10 |
| Levofloxacin | 14 | $134 | $10 |
| Montelukast | 11 | $128 | $12 |
| Ondansetron | 18 | $123 | $7 |
| Alendronate | 13 | $84 | $6 |
2020: 39 drugs
| Valganciclovir | 107 | $80,810 | $755 |
| Valcyte | 12 | $67,220 | $5,602 |
| Tacrolimus | 88 | $17,968 | $204 |
| Atovaquone | 12 | $10,486 | $874 |
| Ambisome | 15 | $10,035 | $669 |
| Mycophenolate Mofetil | 36 | $6,578 | $183 |
| Colistimethate | 15 | $5,490 | $366 |
| Zetia | 12 | $4,378 | $365 |
| Azithromycin | 99 | $3,385 | $34 |
| Itraconazole | 12 | $2,154 | $180 |
| Pantoprazole | 75 | $2,134 | $28 |
| Prednisone | 157 | $1,656 | $11 |
| Azathioprine | 11 | $1,421 | $129 |
| Pravastatin | 83 | $1,390 | $17 |
| Gabapentin | 48 | $951 | $20 |
| Ultra-Fine Short Pen Needle | 13 | $759 | $58 |
| Warfarin | 48 | $630 | $13 |
| Potassium Chloride | 17 | $578 | $34 |
| Sulfamethoxazole-Trimethoprim | 89 | $569 | $6 |
| Albuterol Sulfate Hfa | 11 | $520 | $47 |
| Propranolol | 17 | $516 | $30 |
| Metoclopramide | 26 | $493 | $19 |
| Metoprolol | 47 | $398 | $8 |
| Tamsulosin | 21 | $343 | $16 |
| Ipratropium | 11 | $310 | $28 |
| Mirtazapine | 19 | $290 | $15 |
| Furosemide | 57 | $287 | $5 |
| Omeprazole | 15 | $247 | $16 |
| Sertraline | 22 | $203 | $9 |
| Levofloxacin | 17 | $203 | $12 |
| Famotidine | 13 | $202 | $16 |
| Atorvastatin | 15 | $185 | $12 |
| Spironolactone | 13 | $185 | $14 |
| Amlodipine Besylate | 22 | $178 | $8 |
| Trazodone | 33 | $147 | $4 |
| Cyclobenzaprine | 12 | $125 | $10 |
| Zolpidem | 11 | $91 | $8 |
| Alprazolam | 11 | $68 | $6 |
| Tramadol | 14 | $35 | $3 |
2019: 50 drugs
| Valganciclovir | 143 | $139,083 | $973 |
| Creon | 14 | $35,171 | $2,512 |
| Atovaquone | 20 | $12,920 | $646 |
| Tacrolimus | 107 | $10,426 | $97 |
| Spiriva | 17 | $9,296 | $547 |
| Novolog Flexpen | 18 | $7,470 | $415 |
| Januvia | 12 | $7,248 | $604 |
| Mycophenolate Mofetil | 39 | $3,802 | $97 |
| Clotrimazole | 29 | $3,428 | $118 |
| Azithromycin | 134 | $3,319 | $25 |
| Cefoxitin | 11 | $3,081 | $280 |
| Prograf | 12 | $2,788 | $232 |
| Prednisone | 162 | $1,822 | $11 |
| Pantoprazole | 95 | $1,746 | $18 |
| Pravastatin | 100 | $1,711 | $17 |
| Azathioprine | 24 | $1,400 | $58 |
| Omega-3 Acid Ethyl Esters | 12 | $1,138 | $95 |
| Sulfamethoxazole-Trimethoprim | 79 | $885 | $11 |
| Propafenone | 13 | $718 | $55 |
| Levothyroxine | 41 | $679 | $17 |
| Metoprolol | 13 | $638 | $49 |
| Metoprolol | 65 | $608 | $9 |
| Nystatin | 14 | $604 | $43 |
| Warfarin | 44 | $592 | $13 |
| Metoclopramide | 31 | $582 | $19 |
| Hydralazine | 16 | $504 | $31 |
| Gabapentin | 32 | $491 | $15 |
| Ultra-Fine Short Pen Needle | 11 | $482 | $44 |
| Doxycycline Monohydrate | 18 | $443 | $25 |
| Amlodipine Besylate | 29 | $395 | $14 |
| Potassium Chloride | 18 | $359 | $20 |
| Montelukast | 14 | $342 | $24 |
| Escitalopram | 11 | $342 | $31 |
| Chlorthalidone | 16 | $308 | $19 |
| Atorvastatin | 12 | $307 | $26 |
| Furosemide | 45 | $304 | $7 |
| Omeprazole | 16 | $280 | $18 |
| Trazodone | 27 | $264 | $10 |
| Sertraline | 20 | $217 | $11 |
| Levofloxacin | 22 | $208 | $9 |
| Acetaminophen-Codeine | 20 | $182 | $9 |
| Fluoxetine | 11 | $177 | $16 |
| Amoxicillin-Clavulanate Potass | 17 | $165 | $10 |
| Mirtazapine | 15 | $152 | $10 |
| Cyclobenzaprine | 13 | $106 | $8 |
| Tamsulosin | 13 | $95 | $7 |
| Tramadol | 18 | $95 | $5 |
| Doxazosin Mesylate | 12 | $83 | $7 |
| Amoxicillin | 19 | $57 | $3 |
| Citalopram Hbr | 13 | $56 | $4 |
2018: 41 drugs
| Valganciclovir | 111 | $104,173 | $938 |
| Tigecycline | 14 | $27,052 | $1,932 |
| Januvia | 25 | $11,438 | $458 |
| Tacrolimus | 115 | $10,508 | $91 |
| Advair Diskus | 17 | $8,321 | $489 |
| Esomeprazole Magnesium | 17 | $8,203 | $483 |
| Imipenem-Cilastatin | 15 | $6,679 | $445 |
| Spiriva | 14 | $6,320 | $451 |
| Azithromycin | 144 | $3,823 | $27 |
| Amphotericin B | 11 | $3,650 | $332 |
| Propafenone Hcl Er | 11 | $3,464 | $315 |
| Clotrimazole | 40 | $2,916 | $73 |
| Mycophenolate Mofetil | 13 | $2,493 | $192 |
| Pravastatin | 94 | $2,358 | $25 |
| Azathioprine | 34 | $1,570 | $46 |
| Prednisone | 165 | $1,544 | $9 |
| Sulfamethoxazole-Trimethoprim | 85 | $844 | $10 |
| Pantoprazole | 62 | $791 | $13 |
| Gabapentin | 46 | $771 | $17 |
| Ventolin Hfa | 13 | $717 | $55 |
| Levothyroxine | 40 | $667 | $17 |
| Dapsone | 15 | $642 | $43 |
| Metoprolol | 73 | $573 | $8 |
| Warfarin | 33 | $536 | $16 |
| Escitalopram | 15 | $524 | $35 |
| Ipratropium | 12 | $498 | $41 |
| Amlodipine Besylate | 51 | $472 | $9 |
| Metoprolol | 11 | $437 | $40 |
| Acetaminophen-Codeine | 42 | $382 | $9 |
| Levofloxacin | 21 | $378 | $18 |
| Omeprazole | 15 | $275 | $18 |
| Amoxicillin-Clavulanate Potass | 23 | $267 | $12 |
| Hydralazine | 11 | $248 | $23 |
| Metoclopramide | 19 | $244 | $13 |
| Furosemide | 40 | $242 | $6 |
| Tramadol | 21 | $237 | $11 |
| Alprazolam | 13 | $148 | $11 |
| Trazodone | 19 | $141 | $7 |
| Hydrochlorothiazide | 14 | $86 | $6 |
| Temazepam | 11 | $76 | $7 |
| Amoxicillin | 11 | $55 | $5 |
2017: 45 drugs
| Valcyte | 19 | $111,807 | $5,885 |
| Valganciclovir | 66 | $103,330 | $1,566 |
| Voriconazole | 23 | $16,033 | $697 |
| Advair Diskus | 34 | $15,184 | $447 |
| Prograf | 42 | $12,106 | $288 |
| Spiriva | 28 | $11,767 | $420 |
| Esomeprazole Magnesium | 20 | $7,950 | $397 |
| Mycophenolate Mofetil | 23 | $5,217 | $227 |
| Azithromycin | 112 | $3,637 | $32 |
| Clotrimazole | 29 | $2,658 | $92 |
| Azathioprine | 31 | $2,560 | $83 |
| Pravastatin | 118 | $2,466 | $21 |
| Tacrolimus | 25 | $2,390 | $96 |
| Omega-3 Acid Ethyl Esters | 14 | $1,407 | $100 |
| Prednisone | 127 | $1,375 | $11 |
| Dapsone | 20 | $1,362 | $68 |
| Azelastine | 17 | $1,209 | $71 |
| Proair Hfa | 17 | $968 | $57 |
| Diltiazem | 14 | $853 | $61 |
| Pantoprazole | 58 | $813 | $14 |
| Levothyroxine | 29 | $808 | $28 |
| Duloxetine | 14 | $777 | $56 |
| Sulfamethoxazole-Trimethoprim | 80 | $767 | $10 |
| Warfarin | 38 | $681 | $18 |
| Omeprazole | 39 | $679 | $17 |
| Metoprolol | 69 | $573 | $8 |
| Hydralazine | 26 | $564 | $22 |
| Tamsulosin | 13 | $557 | $43 |
| Levofloxacin | 32 | $470 | $15 |
| Venlafaxine Hcl Er | 15 | $350 | $23 |
| Gabapentin | 27 | $346 | $13 |
| Enalapril Maleate | 11 | $319 | $29 |
| Escitalopram | 15 | $245 | $16 |
| Amlodipine Besylate | 38 | $238 | $6 |
| Acetaminophen-Codeine | 19 | $231 | $12 |
| Hydrocodone-Acetaminophen | 11 | $224 | $20 |
| Metoclopramide | 16 | $171 | $11 |
| Citalopram Hbr | 12 | $162 | $13 |
| Trazodone | 22 | $152 | $7 |
| Alprazolam | 20 | $147 | $7 |
| Amoxicillin-Clavulanate Potass | 12 | $137 | $11 |
| Tramadol | 21 | $127 | $6 |
| Furosemide | 21 | $101 | $5 |
| Montelukast | 13 | $83 | $6 |
| Carvedilol | 13 | $80 | $6 |
2016: 34 drugs
| Valganciclovir | 51 | $84,593 | $1,659 |
| Amphotericin B | 18 | $9,952 | $553 |
| Advair Diskus | 21 | $7,968 | $379 |
| Voriconazole | 13 | $5,485 | $422 |
| Lyrica | 11 | $5,464 | $497 |
| Azithromycin | 93 | $3,244 | $35 |
| Tacrolimus | 33 | $3,181 | $96 |
| Omega-3 Acid Ethyl Esters | 16 | $3,085 | $193 |
| Novolog | 12 | $3,011 | $251 |
| Mycophenolate Mofetil | 22 | $2,548 | $116 |
| Pravastatin | 69 | $1,633 | $24 |
| Clotrimazole | 14 | $1,466 | $105 |
| Azathioprine | 21 | $1,168 | $56 |
| Omeprazole | 44 | $960 | $22 |
| Prednisone | 77 | $713 | $9 |
| Pantoprazole | 26 | $607 | $23 |
| Tamsulosin | 12 | $578 | $48 |
| Metoprolol | 75 | $566 | $8 |
| Sulfamethoxazole-Trimethoprim | 68 | $549 | $8 |
| Levothyroxine | 35 | $517 | $15 |
| Hydrocodone-Acetaminophen | 15 | $365 | $24 |
| Levofloxacin | 20 | $353 | $18 |
| Gabapentin | 16 | $346 | $22 |
| Warfarin | 38 | $289 | $8 |
| Alprazolam | 17 | $205 | $12 |
| Atorvastatin | 14 | $182 | $13 |
| Trazodone | 22 | $176 | $8 |
| Furosemide | 34 | $176 | $5 |
| Metoclopramide | 12 | $172 | $14 |
| Tramadol | 13 | $172 | $13 |
| Diltiazem | 13 | $167 | $13 |
| Citalopram Hbr | 31 | $155 | $5 |
| Zolpidem | 12 | $128 | $11 |
| Amlodipine Besylate | 18 | $118 | $7 |
2015: 32 drugs
| Valganciclovir | 23 | $58,187 | $2,530 |
| Voriconazole | 12 | $17,242 | $1,437 |
| Amikacin Sulfate | 27 | $9,315 | $345 |
| Amphotericin B | 17 | $6,345 | $373 |
| Nexium | 17 | $5,898 | $347 |
| Lyrica | 12 | $5,136 | $428 |
| Humalog Kwikpen U-100 | 12 | $5,121 | $427 |
| Advair Diskus | 13 | $4,114 | $316 |
| Azithromycin | 66 | $2,483 | $38 |
| Tacrolimus | 24 | $1,726 | $72 |
| Pentam 300 | 12 | $1,561 | $130 |
| Mycophenolate Mofetil | 13 | $1,490 | $115 |
| Doxycycline Monohydrate | 13 | $1,128 | $87 |
| Pravastatin | 56 | $1,126 | $20 |
| Proair Hfa | 13 | $659 | $51 |
| Levothyroxine | 28 | $653 | $23 |
| Prednisone | 63 | $562 | $9 |
| Omeprazole | 22 | $511 | $23 |
| Metoprolol | 59 | $421 | $7 |
| Warfarin | 25 | $414 | $17 |
| Sulfamethoxazole-Trimethoprim | 54 | $381 | $7 |
| Metoclopramide | 18 | $350 | $19 |
| Levofloxacin | 24 | $292 | $12 |
| Fluticasone Propionate | 24 | $276 | $12 |
| Zolpidem | 13 | $275 | $21 |
| Acetaminophen-Codeine | 16 | $227 | $14 |
| Alprazolam | 19 | $187 | $10 |
| Furosemide | 46 | $174 | $4 |
| Tramadol | 12 | $161 | $13 |
| Pantoprazole | 17 | $137 | $8 |
| Trazodone | 15 | $91 | $6 |
| Amlodipine Besylate | 13 | $74 | $6 |
2014: 1 drug
| Prednisone | 11 | $90 | $8 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study, Followed By An Open-Label Extension, To Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (Clad) Following Bilateral Lung Transplantation · 2025 | Their institution | $66,885 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study, Followed By An Open-Label Extension, To Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (Clad) Following Bilateral Lung Transplantation · 2024 | Their institution | $50,150 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1578721841
- Licence
- CA C177767, TX Q0406California C177767: Current · expires 2028-06-30Texas Q0406: Active
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-05-23
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5323 Harry Hines Blvd, Dallas, TX, 75390